Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 34 for “"Adefovir"”.
-
Multidrug-Resistant Hepatitis B Virus Resulting From Sequential Monotherapy With Lamivudine, Adefovir, and Entecavir: Clonal Evolution During Lamivudine Plus Adefovir Therapy
… sequential monotherapy with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) during LAM plus ADV salvage therapy. METHODS: Sera were obtained from 6 patients who had developed sequential resistance to LAM, ADV, and ETV before and during LAM plus ADV therapy. The HBV genomes from each …
-
Characterization of the Cytotoxic Activity ODE-adefovir in AML
During drug library screen, we discovered adefovir-dipivoxil as potentially active against AML. Adefovir second-generation formulations, including ODE-adefovir and HDP-adefovir, have been designed to overcome adefovir-dibivoxil pharmacodynamic disadvantages. To characterize the activity of the …
-
Emergence of Adefovir-resistant Mutants after Reversion to YMDD Wild-type in Lamivudine-resistant Patients
… to occur up to 67% by 4 years of therapy. Adefovir dipivoxil (ADV) has been applied for the LAM-resistant patients, and it has shown to be effective against both wild-type and LAM-resistant forms of HBV. A pilot study in patients with LAM resistance showed no differences in HBV DNA …
-
Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
"본 연구에서는 이전에 라미부딘 및 아데포비어 내성을 보였던 환자를 엔테카비어로 전환하여 치료하여 이후 발생된 바이러스 반응, 엔테카비어 내성 및 라미부딘과 아데포비어 내성변종의 발현을 관찰하였다. 대상 환자는 예전에 라미부딘 내성을 보였던 아데포비어 내성 환자 중에서 6개월 이상 엔테카비어를 복용한 40명의 환자를 대상으로 하였으며 이들 환자에서의 바이러스 반응 및 엔테카비어 내성을 모니터링하였다. 전체 10% 환자에서 24주 동안의 엔테카비어 치료로 HBV DNA가 50 (copies/mL) 이하가 되었으며 40명의 환자 중 …
-
Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine resistant chronic hepatitis B patients
BACKGROUNDS: Adefovir dipivoxil effectively inhibits both wild-type and lamivudine-resistant hepatitis B virus replication. The development of adefovir resistance is delayed and infrequent compared with lamivudine resistance. The aim of this study was to characterize the serologic, biochemical and …
-
Association of Lamivudine-Resistant Mutational Patterns with the Antiviral Effect of Adefovir in Patients with Chronic Hepatitis B
… 8 A. Virologic and biochemical response to adefovir 8 B. Antiviral efficacy of Adefovir between the HBeAg-positive and -negative Groups 8 C. Baseline hepatitis B virus polymerase mutations 8 D. Effect of lamivudine-resistant mutational pattern on the virologic and biochemical response to …
-
Analysis of Treatment Effect of Lamivudine, Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis
Background: Add on adefovir (ADV) to ongoing lamivudine (LAM) is an established treatment modality for treatment of LAM resistance with chronic hepatitis B. We assessed the long?term efficacy (median follow-up of 20.18 months) of ADV add-on LAM therapy in 89 LAM-resistant patients. Methods: 89 …
-
Analysis of Treatment Effect of Lamivudine plus Adefovir Add-on Therapy in Patients with Lamivudine Resistant Chronic B-viral Hepatitis
목적: 라미부딘은 만성 B형 간염의 1차 치료제로 널리 사용되어 왔으나 내성 발현이 잦은 단점이 있다. 이러한 단점을 극복하기 위해 아데포비어 병합 치료가 사용되고 있으나 한국인을 대상으로 한 연구 결과는 적은 편이다. 저자들은 라미부딘에 내성인 B형 만성 간염 환자를 대상으로 라미부딘과 아데포비어 병합 치료 효과와 바이러스 돌파 현상을 확인하고자 하였다. 방법: 2005년 8월부터 2010년 10월까지 본원에서 라미부딘 투여 중 내성이 발생한 후 아데포비어를 추가??여 치료한 환자 중 12개월 이상 치료받은 93명을 대상으로 …
-
Η συμβολή της βιοτεχνολογίας (αλληλουχία γονιδίων) στον προσδιορισμό των γονοτύπων και στην ανάδειξη μεταλλάξεων του ιού της ηπατίτιδας Β μετά από αντι-ική θεραπεία
… to detect resistance mutations to lamivudine and adefovir. Using PCR sequencing assay, all mutations in the region of reverse transcriptase of the A-E domains of HBV polymerase could be identified as well as mutations correlated to drug resistance and mutations not correlated to drug resistance. …
-
Ανίχνευση μεταλλαγμένων στελεχών του HBV κατά τη θεραπεία με νουκλεοσιδικά ανάλογα ασθενών με χρόνια ηπατίτιδα Β
… and 20 with decompensated liver disease) or adefovir 10mg daily (47 patients with decompensated disease), and 42 patients with HBeAg negative chronic hepatitis B and resistance to lamivudine (all with compensated disease) who received either a combination of lamivudine and adefovir (28 …
-
Synthesis of phosphorus/sulfur-based antivirals
… chapter. The preparation of the antiviral agent adefovir is detailed in Chapter 2. The derivatisation of adefovir via the corresponding phosphonic dichloride intermediate and under Garegg-Samuelsson reaction conditions is further discussed. The preparation of novel butyl and dibutyl phosphonate …
-
Kinetic assessment by in vitro approaches - A contribution to reduce animals in toxicity testing
… of the selected test compounds (cyclosporine A, adefovir dipivoxil and cisplatinum) regarding their reliability and relevance to respective in vivo pharmacokinetics. Cells were exposed daily or every other day to the test compounds at two concentration levels (toxic and non-toxic) for up to 14 …
-
Genotypisierung und Resistenzbestimmung des Hepatitis-B-Virus durch Pyrosequenzierung
… mit IFN-α sowie den Nukleosidanaloga Lamivudin, Adefovir-Dipivoxil oder Entecavir soll die Virusreplikation blockiert und damit die Häufigkeit der Spätfolgen reduziert werden. Die Kenntnis des HBV-Genotyps sowie bekannter Resistenz-Mutationen des Virusgenoms spielt eine große Rolle für eine …
-
Σημασία των επιπέδων των ενεργοποιημένων αποπτωτικών κασπασών ορού σε ασθενείς με HBeAg αρνητική χρόνια ηπατίτιδα Β με ή χωρίς θεραπεία
… 46 patients with CHB received lamivudine or adefovir monotherapy for ≥12 months. Of the 42 lamivudine treated patients, 23 developed virological breakthroughs and received add-on adefovir therapy for ≥12 months. Levels of K-18 fragments (U/L) were measured blindly in stored serum samples …
-
Επίπεδα HBsAg ορού σε ασθενείς με HBeAg-αρνητική χρόνια ηπατίτιδα Β υπό μακροχρόνια αντιική θεραπεία
… NA(s) for a mean of 66 months (lamivudine: 66, adefovir: 6, lamivudine plus adefovir: 11, telbivudine: 16) and 86 HBeAg-negative CHB patients under entecavir or tenofovir for a mean of 30 months as the comparison group. Results: Compared to baseline, HBsAg levels decreased by a median of 162, …
-
Untersuchung der Dynamik von Resistenzvarianten des Hepatitis-B-Virus unter Drittlinientherapie mit Tenofovir mittels Tiefenpyrosequenzierung bei Patienten mit chronischer Hepatitis-B-Virusinfektion mit Schwerpunkt auf den Adefovir-Resistenzvarianten und Verlauf der HBV-Quasispezies
… jedoch wird ein möglicher negativer Einfluss von Adefovir dipivoxil (ADV)-Resistenzvarianten auf die TDF-Ansprechrate diskutiert. Diese retrospektive Kohortenstudie untersucht die Dynamik von Nukleos(t)id-Analoga (NA)-Resistenzvarianten im HBV-Polymerasegen mit Fokus auf ADV-Resistenzvarianten bei …
-
Assessment of systemic toxicity in vitro using the Adverse Outcome Pathway (AOP) concept: nephrotoxicity due to receptor-mediated endocytosis and lysosomal overload and inhibition of mtDNA polymerase-ɣ as case studies
… number in cells treated with mod-el compounds (adefovir, cidofovir, tenofovir, adefovir dipivoxil, tenofovir disoproxil fumarate). Mitochondrial toxicity (KE2) was measured by project partners using the high-content imaging technique and MitoTracker® whereas cytotoxicity (KE3) was determined by …
-
Active Pharmaceutical Ingredient Based Ionic Liquids for Enhancement of Solubility and Permeability
… alexidine, and two antiviral molecules, adefovir dipivoxil and tenofovir alafenamide, were converted into pharmaceutically beneficial ionic liquids. To demonstrate the flexibility of this technique, these molecules were delivered via three different routes of administration. All routes …
-
Design and synthesis of novel sulfur-containing antiviral analogues
… Our proposed synthetic target, an analogue of Adefovir Dipivoxil, is described alongside our rationale for studying this compound. Chapter Three details the model study which we conducted in order to assess possible synthetic routes to our target molecule. The highlight of this work was the …
-
Επίδραση της αντιϊκής θεραπείας στην απόπτωση των ηπατοκυττάρων σε ασθενείς με χρόνια ιογενή ηπατίτιδα
… the 1st and 2nd LB (17 interferon-alpha and 12adefovir dipivoxil) and 7 patients were used as control group. The primaryandibodies included monoclonal antibodies against bcl-2, bcl-xL and bax proteins,and their expression was studied using the streptavidin-biotin technique.RESULTS: There was no …
Page 1 of 2